Head and Neck Diseases
PRINCIPAL INVESTIGATORS
- Lorena Arribas Hortigüela
- Marc Oliva Bernal
CLINICAL RESEARCHERS
- Carlos Arranz Obispo
- Josep Oriol Bermejo Segú
- Jesús Brenes Castro
- Aina Brunet Garcia
- Enric Cisa Lluis
- Mònica Cos Domingo
- Francesc Cruellas Taischik
- Montserrat Gomà Gallego
- Xavier González Compta
- Miriam Handam Zavarce
- Alicia Lozano Borbalas
- Antonio Mari Roig
- Mireia Melero Luque
- Julio Nogués Orpí
- Anna Penella Prat
- María Plana Serrahima
- Laura Rodriguez Bel
- Jordi Tornero Saltó
- Ricardo Bartel Arensburg
- Aina Brunet García
- Marta Mesalles Ruíz
- Alex Portillo Medina
- Arnaud Gerard Morla
- Silvia Cuscó Albors
- Marta Fulla Campí
- Henri R Lares Archer
- Eva Baguda Molinas
COLLABORATORS
- Aleix Rovira Casas
SCIENTIFIC SUPPORT
- Maria Sospedra Martinez
Cancer
Oncobell
Scientific production
26
PAPERS
Average IF: 6,943
6
LED PAPERS
Average IF: 4,485
3 PUBLICATIONS IN FIRST DECILE
11 PUBLICATIONS IN FIRST QUARTILE
18 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Haddad,RI;Harrington,K;Tahara,M;Ferris,RL;Gillison,M;Fayette,J;Daste,A et al, Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651., J. Clin. Oncol., 2022;doi:10.1200/JCO.22.00332,
- Salawu,A;Hernando Calvo,A;Chen,RY;Araujo,DV;Oliva,M;Liu,ZA;Siu,LL, Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials., Eur. J. Cancer, 2022;173167-177, doi:10.1016/j.ejca.2022.06.045,
- Hernando Calvo,A;Salawu,A;Chen,RY;Araujo,DV;Oliva,M;Liu,ZA;Siu,LL, A risk stratification model for toxicities in phase 1 immunotherapy trials., Eur. J. Cancer, 2022;17511-18, doi:10.1016/j.ejca.2022.08.003,
- Arribas,L;Sabaté Llobera,A;Domingo,MC;Taberna,M;Sospedra,M;Martin,L;González Tampán,AR et al, Assessing dynamic change in muscle during treatment of patients with cancer: Precision testing standards., Clin. Nutr., 2022;41(5):1059-1065, doi:10.1016/j.clnu.2022.03.016,
- Pons Escoda,A;Garcia Ruiz,A;Naval Baudin,P;Grussu,F;Fernandez,JJS;Simo,AC;Sarro,NV et al, Voxel-level analysis of normalized DSC-PWI time-intensity curves: a potential generalizable approach and its proof of concept in discriminating glioblastoma and metastasis., Eur Radiol, 2022;32(6):3705-3715, doi:10.1007/s00330-021-08498-1,
Research highlights
PROJECTS
2Granted competitive projects
1 Ongoing competitive project
6 Started clinical trials
18 Ongoing clinical trials
2 Started non competitive projects
2 Ongoing non competitive projects
PUBLISHED WORKS
1 Thesis
4 Clinical guidelines
Selected projects
- 20ACL093. A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 OR PLACEBO IN COMBINATION WITH PEMBROLIZUMAB FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA. Budget: 236335,84. 2020- . PI: Plana Serrahima, María.
- 21ACL104. A RANDOMIZED, DOUBLE-BLIND PLACEBOCONTROLLED, PHASE 3 STUDY OF DEBIO 1143 IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY AND STANDARD FRACTIONATION INTENSITY-MODULATED RADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK, SUITABLE FOR DEFINITIVE CHEMORADIOTHERAPY (TRILYNX). Budget: 173660,76. 2021- . PI: Oliva Bernal, Marc.
- 2022-232-1. A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors. Seagen Inc. Budget: 171306,45. 2022- . PI: Oliva Bernal, Marc.
- 20ACL181. ESTUDIO DE FASE II, ABIERTO Y MULTICÉNTRICO DE AL101 EN PACIENTES CON CARCINOMA ADENOIDE QUÍSTICO (ACC) CON MUTACIONES ACTIVADORAS NOTCH. Budget: 97497. 2020- . PI: Oliva Bernal, Marc.
- PSJ22006. MoleculaR profiling and ImmunophEnotyping as preDictors of outcomE in non-metastatic SalIvary Gland carciNomas (REDESIGN). Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC). Budget: 80000. 2022-2024. PI: Oliva Bernal, Marc.